Janet Woodcock reportedly ruled out of being kept on in FDA's top job

23 August 2021

The acting Commissioner of the US Food and Drug Administration (FDA) will not get the job permanently, according to a Bloomberg report.

Unnamed sources quoted by the report claim that President Joe Biden’s administration has ruled out nominating her as permanent head of the agency.

Dr Woodcock has been in the job since President Biden took office, but her spell in charge has not been without controversy, and it is the disputed approval of the Alzheimer’s drug Aduhelm (aducanumab) in June that has been linked strongly with the decision not to keep her on.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK